74 related articles for article (PubMed ID: 38496907)
1. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
2. Recurrent Wnt medulloblastoma treated with marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue: a dual case report and review of the literature.
Harris MK; Shatara M; Funk Z; Stanek J; Boué DR; Jones J; Finlay JL; Abdelbaki MS
Childs Nerv Syst; 2022 Feb; 38(2):465-472. PubMed ID: 33948723
[TBL] [Abstract][Full Text] [Related]
3. Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors.
Shatara M; Blue M; Stanek J; Liu YA; Prevedello DM; Giglio P; Puduvalli VK; Gardner SL; Allen JC; Wong KK; Nelson MD; Gilles FH; Adams RH; Pauly J; O'Halloran K; Margol AS; Dhall G; Finlay JL
Neurooncol Pract; 2024 Apr; 11(2):188-198. PubMed ID: 38496907
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours.
Aykan MB; Yildiran GS; Akcan E; Acar R; Erturk I; Karadurmus N
J Coll Physicians Surg Pak; 2022 Jul; 32(7):880-884. PubMed ID: 35795936
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.
Takada A; Ii N; Hirayama M; Toyoda H; Matsubara T; Toyomasu Y; Kawamura T; Daimon T; Sakuma H; Nomoto Y
J Neurosurg Pediatr; 2018 Nov; 23(3):317-324. PubMed ID: 30497152
[TBL] [Abstract][Full Text] [Related]
6. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.
Modak S; Gardner S; Dunkel IJ; Balmaceda C; Rosenblum MK; Miller DC; Halpern S; Finlay JL
J Clin Oncol; 2004 May; 22(10):1934-43. PubMed ID: 15143087
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors.
Schönberger S; Mohseni MM; Ellinger J; Tran GVQ; Becker M; Claviez A; Classen CF; Hermes B; Driever PH; Jorch N; Lauten M; Mehlitz M; Schäfer N; Scheer-Preiss J; Schneider DT; Troeger A; Calaminus G; Dilloo D
J Cancer Res Clin Oncol; 2023 Feb; 149(2):791-802. PubMed ID: 35171328
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts.
Takami H; Elzawahry A; Mamatjan Y; Fukushima S; Fukuoka K; Suzuki T; Yanagisawa T; Matsushita Y; Nakamura T; Satomi K; Tanaka S; Mukasa A; Saito N; Kanamori M; Kumabe T; Tominaga T; Kobayashi K; Nagane M; Iuchi T; Tamura K; Maehara T; Sugiyama K; Yoshimoto K; Sakai K; Nonaka M; Asai A; Yokogami K; Takeshima H; Narita Y; Shibui S; Nakazato Y; Hama N; Totoki Y; Kato M; Shibata T; Nishikawa R; Matsutani M; Ichimura K
Neuro Oncol; 2022 Aug; 24(8):1246-1258. PubMed ID: 35137206
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors.
Porfyriou E; Letsa S; Kosmas C
World J Clin Oncol; 2021 Sep; 12(9):746-766. PubMed ID: 34631440
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors.
Abu-Arja MH; Osorio DS; Lassaletta A; Graham RT; Coven SL; Stanek JR; Bouffet E; Finlay JL; Abdelbaki MS
Pediatr Blood Cancer; 2022 Jan; 69(1):e29365. PubMed ID: 34558189
[TBL] [Abstract][Full Text] [Related]
12. Relapsing intracranial germ cell tumours warrant retreatment.
Callec L; Lardy-Cleaud A; Guerrini-Rousseau L; Alapetite C; Vignon L; Chastagner P; Frappaz D; Faure-Conter C
Eur J Cancer; 2020 Sep; 136():186-194. PubMed ID: 32711377
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
Perez-Somarriba M; Moreno-Tejero ML; Rozas MI; Pelaez I; Madero L; Lassaletta A
Pediatr Blood Cancer; 2020 Feb; 67(2):e28089. PubMed ID: 31724795
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.
Fangusaro J; Wu S; MacDonald S; Murphy E; Shaw D; Bartels U; Khatua S; Souweidane M; Lu HM; Morris D; Panigrahy A; Onar-Thomas A; Fouladi M; Gajjar A; Dhall G
J Clin Oncol; 2019 Dec; 37(34):3283-3290. PubMed ID: 31545689
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
